Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661)

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

This public procurement record has 1 release in its history.

Award

10 Jul 2024 at 01:00

PCS Notice - Website Contract Award Notice
Summary of the contracting process

The Common Services Agency (NHS National Services Scotland) (NSS) has completed the procurement process for the "NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B" in Edinburgh, UK. The industry category is Health, and relevant key dates include the award date on 10th July 2024. The procurement stage was an open procedure.

This tender provides opportunities for large-scale suppliers in the health industry to supply products for treating Blood Disorders, including Haemophilia A & B to NHS Scotland. Businesses involved in the supply of pharmaceutical products and services, such as Takeda UK Limited, Pfizer Limited, and Octapharma Ltd, would be well-suited to compete for this tender and potentially grow their businesses through this framework agreement.

How relevant is this notice?

Notice Information

Notice Title

NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661)

Notice Description

Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland.

Lot Information

Standard Half-life Recombinant Factor VIII

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Enhanced Half-life Recombinant Factor VIII

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Enhanced Half-life Recombinant Factor VIII

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Eftrenonacog alfa (rFIX EHL)

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Eftrenonacog alfa (rFIX EHL)

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Nonacog beta pegol (rFIX EHL)

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

rFIX - Standard Half Life

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Recombinant Factor VII

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Porcine Factor VIII - susoctocog alfa

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Factor VIII Inhibitor Bypassing Fraction

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Factor IX - High Purity Factor IX

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Factor X

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Factor XIII - Plasma Derived

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Factor XIII - Recombinant

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Von willebrands factor / Factor VIII

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Von willebrands factor - Plasma Derived

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Von willebrands factor - Recombinant

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Fibrinogen Concentrate

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Prothrombin Complex dried

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Protein C Concentrate

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Fresh Frozen Plasma (all blood groups)

NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-r6ebe6-0000772000
Publication Source
Public Contracts Scotland
Latest Notice
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL509597
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
PCS Notice - Website Contract Award Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33141530 - Blood coagulants

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£85,293,871 £10M-£100M

Notice Dates

Publication Date
10 Jul 20242 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
31 May 20242 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Not Specified
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
EDINBURGH
Postcode
EH12 9EB
Postcode Area
Edinburgh
Country
Scotland
Major Region (ITL 1)
TLM Scotland
Basic Region (ITL 2)
TLM1 East Central Scotland
Small Region (ITL 3)
TLM13 City of Edinburgh
Delivery Location
TLM Scotland
Local Authority
City of Edinburgh
Electoral Ward
Drum Brae/Gyle
Westminster Constituency
Edinburgh South West

Supplier Information

Number of Suppliers
9
Supplier Names

Bio Products Laboratory

CSL Behring

LFB Biopharmaceuticals Ltd

Novo Nordisk Ltd

Octapharma Ltd

Pfizer Limited

Roche Products Ltd

Swedish Orphan Biovitrum Ltd

Takeda UK Limited

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...